

Thomas Frisell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5141364/publications.pdf>

Version: 2024-02-01

91
papers

4,106
citations

117625

34
h-index

123424

61
g-index

94
all docs

94
docs citations

94
times ranked

5665
citing authors

#	ARTICLE	IF	CITATIONS
1	Sibling Comparison Designs. Epidemiology, 2012, 23, 713-720.	2.7	401
2	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	9.0	342
3	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 2016, 79, 950-958.	5.3	190
4	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurology, 2018, 75, 320.	9.0	155
5	Familial Risks and Heritability of Rheumatoid Arthritis: Role of Rheumatoid Factor/Anti-“Citrullinated Protein Antibody Status, Number and Type of Affected Relatives, Sex, and Age. Arthritis and Rheumatism, 2013, 65, 2773-2782.	6.7	153
6	Familial clustering of suicide risk: a total population study of 11.4 million individuals. Psychological Medicine, 2011, 41, 2527-2534.	4.5	148
7	Violent crime runs in families: a total population study of 12.5 million individuals. Psychological Medicine, 2011, 41, 97-105.	4.5	135
8	Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice. JAMA Internal Medicine, 2017, 177, 1605.	5.1	124
9	The 1% of the population accountable for 63% of all violent crime convictions. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 559-571.	3.1	107
10	Psychiatric morbidity associated with same-sex sexual behaviour: influence of minority stress and familial factors. Psychological Medicine, 2010, 40, 315-324.	4.5	103
11	Maternal body mass index during early pregnancy, gestational weight gain, and risk of autism spectrum disorders: Results from a Swedish total population and discordant sibling study. International Journal of Epidemiology, 2015, 44, 870-883.	1.9	99
12	Maternal and Fetal Genetic Contributions to Postterm Birth: Familial Clustering in a Population-Based Sample of 475,429 Swedish Births. American Journal of Epidemiology, 2013, 177, 531-537.	3.4	93
13	Carryover Effects in Sibling Comparison Designs. Epidemiology, 2016, 27, 852-858.	2.7	90
14	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	5.3	86
15	Family history of rheumatoid arthritis: an old concept with new developments. Nature Reviews Rheumatology, 2016, 12, 335-343.	8.0	82
16	TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Annals of the Rheumatic Diseases, 2015, 74, 2137-2143.	0.9	79
17	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the Rheumatic Diseases, 2021, 80, 1086-1093.	0.9	79
18	Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Annals of the Rheumatic Diseases, 2021, 80, 169-175.	0.9	66

#	ARTICLE	IF	CITATIONS
19	Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 974.	9.0	65
20	Heritability, Assortative Mating and Gender Differences in Violent Crime: Results from a Total Population Sample Using Twin, Adoption, and Sibling Models. Behavior Genetics, 2012, 42, 3-18.	2.1	64
21	Prolonged second stage of labor is associated with low Apgar score. European Journal of Epidemiology, 2015, 30, 1209-1215.	5.7	63
22	How well do ACPA discriminate and predict RA in the general population: a study based on 12â€¦590 population-representative Swedish twins. Annals of the Rheumatic Diseases, 2017, 76, 119-125.	0.9	60
23	Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Annals of the Rheumatic Diseases, 2016, 75, 1272-1278.	0.9	59
24	Apgar Score Components at 5ÂMinutes: Risks and Prediction of Neonatal Mortality. Paediatric and Perinatal Epidemiology, 2017, 31, 328-337.	1.7	59
25	Hospital Admission With Infection During Childhood and Risk for Psychotic Illness--A Population-based Cohort Study. Schizophrenia Bulletin, 2014, 40, 1518-1525.	4.3	56
26	Sexual offending runs in families: A 37-year nationwide study. International Journal of Epidemiology, 2015, 44, 713-720.	1.9	55
27	Anabolic androgenic steroids and violent offending: confounding by polysubstance abuse among 10â€‰%365 general population men. Addiction, 2015, 110, 100-108.	3.3	55
28	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology, 2015, 44, 1706-1721.	1.9	53
29	The Association Between Schizophrenia and Rheumatoid Arthritis: A Nationwide Population-Based Swedish Study on Intraindividual and Familial Risks. Schizophrenia Bulletin, 2014, 40, 1552-1559.	4.3	52
30	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	10.2	45
31	Comparative effectiveness of rituximab relative to IFN-Î² or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis Journal, 2018, 24, 1087-1095.	3.0	44
32	Risk Factors for the Rapid Increase in Risk of Acute Coronary Events in Patients With Newâ€œOnset Rheumatoid Arthritis: A Nested Caseâ€œControl Study. Arthritis and Rheumatology, 2015, 67, 2845-2854.	5.6	42
33	Validation of the Swedish Multiple Sclerosis Register. Epidemiology, 2019, 30, 230-233.	2.7	42
34	Is the Association between General Cognitive Ability and Violent Crime Caused by Family-Level Confounders?. PLoS ONE, 2012, 7, e41783.	2.5	38
35	Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. Annals of the Rheumatic Diseases, 2016, 75, 183-189.	0.9	36
36	Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Annals of the Rheumatic Diseases, 2018, 77, 650-657.	0.9	36

#	ARTICLE	IF	CITATIONS
37	Invited Commentary: Sibling-Comparison Designs, Are They Worth the Effort?. American Journal of Epidemiology, 2021, 190, 738-741.	3.4	33
38	To What Extent Is the Familial Risk of Rheumatoid Arthritis Explained by Established Rheumatoid Arthritis Risk Factors?. Arthritis and Rheumatology, 2015, 67, 352-362.	5.6	32
39	Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 85-93.	3.0	32
40	Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology, 2022, 61, 1810-1818.	1.9	31
41	Bipolar Disorder and Violent Crime: Time at Risk Reanalysis. Archives of General Psychiatry, 2010, 67, 1325.	12.3	27
42	Causal Interpretation of Between-Within Models for Twin Research. Epidemiologic Methods, 2012, 1, .	0.9	27
43	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology, 2019, 26, 1060-1067.	3.3	27
44	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	3.8	25
45	Sibling Comparison Studies. Annual Review of Statistics and Its Application, 2022, 9, 71-94.	7.0	25
46	Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466 686 births. BMJ, The, 2014, 349, g4984-g4984.	6.0	23
47	Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology, 2019, 58, 1367-1377.	1.9	22
48	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
49	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open, 2018, 4, e000655.	3.8	21
50	Familial aggregation and heritability of ankylosing spondylitis â€“ a Swedish nested caseâ€“control study. Rheumatology, 2020, 59, 1695-1702.	1.9	21
51	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.9	18
52	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology, 2022, 61, 3952-3962.	1.9	17
53	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	3.4	16
54	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.9	16

#	ARTICLE	IF	CITATIONS
55	Does a family history of RA influence the clinical presentation and treatment response in RA?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1120-1125.	0.9	13
56	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021, 7, e001987.	3.8	13
57	Uptake of rheumatology biosimilars in the absence of forced switching. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 499-504.	3.1	12
58	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
59	What Is the Persistence to Methotrexate in Rheumatoid Arthritis, and Does Machine Learning Outperform Hypothesis-Based Approaches to Its Prediction?. <i>ACR Open Rheumatology</i> , 2021, 3, 457-463.	2.1	11
60	Validity of the Gender Dysphoria diagnosis and incidence trends in Sweden: a nationwide register study. <i>Scientific Reports</i> , 2021, 11, 16168.	3.3	11
61	Association of height and violent criminality: results from a Swedish total population study. <i>International Journal of Epidemiology</i> , 2014, 43, 835-842.	1.9	10
62	Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2017-2026.	1.8	10
63	Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. <i>RMD Open</i> , 2020, 6, e001201.	3.8	9
64	Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e1574-e1584.	1.1	9
65	Generalizability and effect measure modification in sibling comparison studies. <i>European Journal of Epidemiology</i> , 2022, 37, 461-476.	5.7	9
66	Concordance of Non-“Low-Risk Disease Among Pairs of Brothers With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1847-1852.	1.6	8
67	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. <i>Rheumatology</i> , 2019, 58, 1510-1511.	1.9	8
68	Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1532-1539.	3.0	8
69	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. <i>RMD Open</i> , 2020, 6, e001363.	3.8	8
70	A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy “ results from a Swedish cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 288.	3.5	7
71	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. <i>Rheumatology</i> , 2022, 61, 3596-3605.	1.9	7
72	Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 683-687.	0.9	6

#	ARTICLE	IF	CITATIONS
73	Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Annals of the Rheumatic Diseases, 2022, 81, 433-439.	0.9	6
74	Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Annals of the Rheumatic Diseases, 2022, 81, 729-736.	0.9	6
75	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1512-1518.	2.0	5
76	Risk of depression in multiple sclerosis across disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 632-641.	3.0	5
77	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Network Open, 2021, 4, e2136697.	5.9	5
78	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	3.8	4
79	Violent crime among Swedish military veterans after deployment to Afghanistan: a population-based matched cohort study. International Journal of Epidemiology, 2019, 48, 1604-1613.	1.9	3
80	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. Rheumatology, 2019, 58, 1507-1509.	1.9	3
81	OP0226...SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDs: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
82	FRI0118...INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDs: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
83	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology, 2022, 61, 4286-4296.	1.9	2
84	Paternal violent criminality and preterm birth: a Swedish national cohort study. BMC Pregnancy and Childbirth, 2020, 20, 307.	2.4	1
85	Maternal and Fetal Genetic Contributions to Postterm Birth. Obstetrical and Gynecological Survey, 2013, 68, 495-497.	0.4	0
86	Reply. Annals of Neurology, 2016, 80, 791-792.	5.3	0
87	THU0076...THE IMPACT OF VARYING EXCLUSION CRITERIA ON TREATMENT RESPONSE: REAL-WORLD EVIDENCE TO GUIDE THE DESIGN OF FUTURE CLINICAL TRIALS. , 2019, , .		0
88	FRI0369...TOWARDS MORE PRECISE ESTIMATES OF THE FAMILIAL AGGREGATION AND HERITABILITY OF ANKYLOSING SPONDYLITIS - A SWEDISH NESTED CASE-CONTROL STUDY. , 2019, , .		0
89	FRI0082...EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND) BETWEEN FIVE NATIONAL REGISTERS. , 2019, , .		0
90	Response to: "Inflammatory and non-inflammatory triggers of acute coronary syndromes" by Eyuboglu. Annals of the Rheumatic Diseases, 2020, 79, e50-e50.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data. Clinical Pharmacology and Therapeutics, 2022, 112, 836-845.	4.7	0